AI Article Synopsis
- The therapeutic window for antiarrhythmic drugs is narrower compared to other medications, highlighting the importance of consistency in treatment.
- A case report of a 78-year-old male revealed that switching from brand name cibenzoline to its generic form led to a recurrence of arrhythmias and palpitations.
- Restarting the brand name cibenzoline resulted in complete suppression of the arrhythmias, demonstrating significant differences in drug effectiveness between the brand and its generic counterpart.
Article Abstract
In antiarrhythmic drugs, the therapeutic window is narrower than in other drugs. Brand name and generic drugs do not use the same inactive ingredients and binder substances. We report a 78-year-old male patient who had been treated for asymptomatic atrial fibrillation and atrial/ventricular premature contractions. Brand name cibenzoline had completely suppressed all arrhythmias. When the medication was changed to the generic drug, the patient showed frequent palpitations and arrhythmias. After restarting the brand-name drug, the arrhythmias were completely suppressed again. These results showed clear differences between brand name and generic cibenzoline in a specific patient. This report is the first case to describe the diminished effectiveness of generic oral cibenzoline.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387168 | PMC |
| http://dx.doi.org/10.7759/cureus.41164 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!